NASDAQ:STTK Shattuck Labs Q4 2025 Earnings Results & Report $5.53 +0.20 (+3.75%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$5.54 +0.01 (+0.18%) As of 10/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Shattuck Labs met analyst earnings expectations and missed on revenue in its Q4 2025 results, released March 5, 2026. The company reported EPS of -$0.12 versus the -$0.12 consensus estimate, while revenue of ($1.00) million fell short of the $0.17 million estimate by $1.17 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 5, 2026TimeBefore Market OpensConference Call6:30 AM ET Shattuck Labs EPS ResultsActual EPS-$0.12Consensus EPS -$0.12Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersShattuck Labs Revenue ResultsActual Revenue($1.00) millionExpected Revenue$0.17 millionBeat/MissMissed by -$1.17 millionYoY Revenue GrowthN/AUpcoming EarningsShattuck Labs' Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Shattuck Labs Q4 2025 Earnings FAQ Did Shattuck Labs beat earnings estimates for Q4 2025? Shattuck Labs (NASDAQ:STTK) reported earnings of -$0.12 per share for Q4 2025, matching the consensus estimate of -$0.12. The report was announced on Thursday, March 5, 2026. What was Shattuck Labs' revenue for Q4 2025? Shattuck Labs reported revenue of ($1.00) million for Q4 2025, against a consensus estimate of $0.17 million. When is Shattuck Labs' next earnings date? Shattuck Labs' next earnings date is estimated for Tuesday, November 10, 2026. MarketBeat tracks confirmed and estimated earnings dates for Shattuck Labs on the company's earnings history page. Shattuck Labs Earnings HeadlinesShattuck Labs (NASDAQ:STTK) vs. Exicure (NASDAQ:XCUR) Critical ContrastOctober 13 at 8:17 AM | americanbankingnews.comShattuck Labs Announces Two Poster Presentations at UEG Week 2026October 13 at 8:00 AM | globenewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets. | Weiss Ratings (Ad)UBS Initiates Shattuck Labs at Buy With $17 Price TargetOctober 12, 2026 | marketscreener.comMShattuck Labs (STTK) Receives a Buy from Leerink PartnersOctober 5, 2026 | theglobeandmail.comShattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease DrugOctober 1, 2026 | finance.yahoo.comSee More Shattuck Labs Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Shattuck Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shattuck Labs and other key companies, straight to your email. Email Address About Shattuck LabsShattuck Labs (NASDAQ:STTK) is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create biologic medicines that combine immune checkpoint blockade with immune-cell activation in a single therapeutic construct. Shattuck’s pipeline has included investigational ARC fusion proteins intended to alter the tumor microenvironment and stimulate immune responses against cancer cells. Its lead programs have been evaluated in clinical studies involving advanced solid tumors and hematologic malignancies, including research into therapies targeting CD47 and CD40 ligand pathways. The company continues to assess applications of its platform across oncology and potentially other disease areas. Shattuck Labs was founded in 2016 and maintains operations in the United States. The company is led by Taylor Schreiber, M.D., Ph.D., who serves as president and chief executive officer. Its therapies remain investigational and are subject to clinical testing and regulatory review.View Shattuck Labs ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
